EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. is a federal contractor, registered under UEI CNPVCR8DK7M8 and CAGE code 057Y1. It has been awarded $2,861,158,700 in federal contracts. Primary work spans Research and Development in Biotechnology, Biological Product (except Diagnostic) Manufacturing, and Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services, Department Of Defense, and Other agencies (1 agencies, <0.5% each).
Contact Information
Registration and classification details
Registration
UEI Code
CNPVCR8DK7M8CAGE Code
057Y1Entity Structure
Corporate Entity (Not Tax Exempt)Established
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
Emergent Product Development Gaithersburg Inc. specializes in the advanced development and manufacturing of biological countermeasures, with deep expertise in biotechnology research, vaccine candidate optimization, and clinical-scale product development. The contractor delivers end-to-end solutions ...
Emergent Product Development Gaithersburg Inc. specializes in the advanced development and manufacturing of biological countermeasures, with deep expertise in biotechnology research, vaccine candidate optimization, and clinical-scale product development. The contractor delivers end-to-end solutions for medical countermeasures against high-consequence pathogens, including filoviruses and anthrax, leveraging proprietary platforms such as adjuvanted vaccine formulations and novel immunotherapeutic constructs. Their technical proficiency spans preclinical to late-stage development, including GMP manufacturing of biological products, clinical trial support, and regulatory-aligned process scaling, with a demonstrated focus on accelerating timelines for public health emergencies. The company maintains a sustained partnership with the Department of Health and Human Services, particularly through the Biomedical Advanced Research and Development Authority (BARDA), delivering critical R&D and manufacturing capabilities for national preparedness initiatives. Their work for HHS centers on advancing medical countermeasures under the Project BioShield framework, while a prior engagement with the Department of Defense involved clinical evaluation of analgesic therapeutics, indicating cross-agency adaptability in life sciences support. Emergent Product Development Gaithersburg Inc. operates primarily under NAICS codes 541711 and 541714, focusing on biotechnology R&D excluding nanobiotechnology, and 325414 for biological product manufacturing. This positions them as a niche provider of vaccine and therapeutic development services tailored to federal biodefense and pandemic response mandates, bridging the gap between discovery and deployable medical solutions. As a 2L entity based in Gaithersburg, Maryland, the company is strategically located within the National Capital Region’s biopharmaceutical corridor. While no government certifications are listed, their consistent engagement with BARDA and adherence to federal biological product standards reflect a mature, compliance-driven operational framework aligned with federal procurement expectations.
Key Performance Metrics
Awards Count
30
All time
Active
3
Currently performing
Completed
27
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
Award Analytics & Distribution
Compete with EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Track the contractors you bid against, and the work they win
Award history, agency mix, and NAICS coverage for EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
AI-powered matching against your own capabilities and past performance
Teaming and subcontracting signals on every award
Automated alerts when a competitor wins in your market
Join 750+ contractors already using CLEATUS
